Rezolute gets FDA recommendation for pre-BLA meeting ahead of ersodetug BLA submission

Rezolute announced that the FDA, following a preliminary review of detailed data from the Phase 3 sunRIZE study of ersodetug for hypoglycemia due to congenital hyperinsulinism, recommended a pre-BLA meeting ahead of the BLA submission.

Detected & updated continuously · Source: Nebula